ANTI-WRINKLE* treatment comparison

	Dysport® C. botulinum type A toxin – haemagglutinin complex (abobotulinum toxin A)[1]	Botox® (botulinum toxin type A)[2]	Xeomin® (incobotulinum toxin A)[3]
How long until treatment results can be seen?†	**2-3 days**[1]	**Within 7 days**[2]	**2-3 days**[3]
Duration of treatment results†	Up to **5 months**[1]	At least **4 months**[2]	Up to **4 months**[3]
Incidence of neutralising antibody formation in aesthetic use	**Is low when dosed as per PI**[4]	Is low when dosed as per PI[4]	Is low when dosed as per PI[4]
Australian approval date	**2000**[1]	1999[2]	2014[3]
Are complimentary custom syringes supplied?	**Yes with every Dysport order**	No	No
Unit of measurement (reconstitution volume)‡	**500 unit vial of Dysport + 2.5 mL saline = 200 u/mL**	100 unit vial of BOTOX + 2.5 mL saline = 40 u/mL	100 unit vial of Xeomin + 2.5 mL saline = 40 u/mL

*Glabellar lines and lateral canthal lines. †In glabellar lines.
‡The dosing units of Dysport are specific to the product and are not interchangeable with other botulinum toxin products.

Quick reconstitution volume calculator

500U Dysport vial = 2.5mL
300U Dysport vial = 1.5mL
125U Dysport vial = 0.63mL
of normal saline for injection

Volume mL	0.01	0.025	0.05	0.10	0.15	0.20	0.25	0.30
Dysport units	2	5	10	20	30	40	50	60

Treatment of glabellar lines[1]

Draw up volume = **0.25 mL**



0.3 mL Custom Dysport syringe

0.3 mL Insulin syringe

Treatment of lateral canthal lines[1]

Draw up volume = **0.30 mL**



0.3 mL Custom Dysport syringe

0.3 mL Insulin syringe

GALDERMA



Dysport®

C. BOTULINUM TYPE A TOXIN – HAEMAGGLUTININ COMPLEX

GALDERMA

For Dysport PBS funding information, refer to http://www.pbs.gov.au/. Please review the Dysport Product Information before prescribing, available at www.galderma.com.au or by calling Galderma on 1800 800 765.

Dysport®: Clostridium botulinum type A toxin-haemagglutinin complex (125, 300, 500 IPSEN UNITS/vial). **Indications:** Symptomatic treatment of focal spasticity affecting the upper and lower limbs in adults; spasmodic torticollis in adults; symptomatic treatment of lower limb focal spasticity in children aged 2 years of age and older ; blepharospasm in adults; hemifacial spasm in adults; moderate to severe glabellar lines and / or lateral canthal lines (crow's feet) in adults. **Contraindications:** Hypersensitivity to ingredients; myasthenia gravis or Eaton-Lambert (myasthenic) syndrome; infection at proposed injection site. **Precautions:** The units of Dysport are not interchangeable with other preparations of botulinum type A toxin. Use lowest effective dose and do not exceed recommended dosages and frequencies of administration; adverse effects from toxin distribution to sites remote from the site of administration have been reported (excessive muscle weakness). Use with extreme caution in patients with breathing and swallowing difficulties, sub-clinical or clinical evidence of neuromuscular transmission defects (including drug-induced), and prolonged bleeding times. Use with extreme caution in paediatric patients who have significant neurologic debility, dysphagia, or have a recent history of aspiration pneumonia or lung disease. Antibody formation to botulinum toxin may occur rarely; contains small amount of human albumin so the risk of transmission of viral infection cannot be excluded; ensure ready availability of adrenaline injection in cases of anaphylactic reaction; use in pregnancy only if benefit justifies risk. **Drug Interactions:** Any drugs which interfere with neuromuscular transmission (e.g. muscle relaxants, aminoglycoside antibiotics). **Adverse Effects:** common to very common depending on indication: asthenia, fatigue, influenza-like illness, injection site pain/bruising/swelling/erythema/pruritis/rash/paraesthesia/haematoma; dysphagia, falls; headache, dizziness, facial paresis, blurred vision, visual acuity reduced, dysphonia, dyspnoea, dry mouth, muscle weakness, neck pain, musculoskeletal pain, myalgia, pain in extremity, musculoskeletal stiffness; urinary incontinence, gait disturbance; ptosis, diplopia, dry eyes, lacrimation increased, eyelid oedema; asthenopia, muscle twitching; periorbital haematoma. **Dose:** The units of Dysport are not interchangeable with other preparations of botulinum type A toxin. Recommended minimum interval between treatments is 12 weeks. Focal spasticity of upper limb: up to 1000 units. Focal spasticity of lower limb: up to 1500 units. Spasmodic torticollis: 250-1000 units. Focal spasticity of lower limb in children aged 2 years of age and older: 15-30 units/kg bodyweight, up to a maximum of 1000 units. Blepharospasm & hemifacial spasm: 40-120 units/eye. Glabellar lines: 50 units. Lateral Canthal lines: 30 units per side. **Administration:** Intramuscular injection for all indications except blepharospasm /hemifacial spasm where it is injected subcutaneously. **Storage:** 2°C - 8°C.

References: 1. Dysport Approved Product Information. **2.** Botox Approved Product Information. **3.** Xeomin Approved Product Information. **4.** Field M *et al. Toxins (Basel)*. 2019;11(2):115.

Galderma Australia Pty Ltd, 13B Narabang Way, Belrose NSW 2085. Phone: 1800 144 944, Fax: +61 2 9986 1699, ABN 12 003 976 930. Dysport is distributed by Galderma Australia Pty Ltd for the glabellar lines and lateral canthal lines indication only. Sponsor: Ipsen Pty Ltd, Level 2, Building 4, Brandon Office Park, 540 Springvale Road, Glen Waverley, Victoria 3150 Australia.

GALDERMA